Premaitha acquires Taiwan NIPT provider in £7.2m deal

Premaitha acquires Taiwan NIPT provider in £7.2m deal

BIOTECH company Premaitha Health, the developer of the ground-breaking non-invasive prenatal test IONA, has acquired Taiwan-based Yourgene Bioscience which is development the treatment in Asia in a deal for about £7.2m.

Manchester-based Premaitha has announced the conditional acquisition of the entire issued share capital of Yourgene, a significant Asian NIPT bioinformatics specialist based in Taiwan. It has a commercial hub in Singapore and annual sales of circa £2m generated from across South East Asia and India, and is broadly break-even at those trading levels.

Premaitha now supplies more than 50 UK hospitals through client laboratories and in-house clinical service and the NHS is to make non-invasive prenatal screening tests (NIPT) available for high risk cases from 2018.

Premaitha chief executive Dr Stephen Little said: “We are very pleased with the progress being made with the IONA test in the regions where we are operational, and we have positioned ourselves to take advantage of the exceptional opportunities emerging in the Middle East and Asia. Within Europe and the Middle East we continue to make excellent progress with a substantial pipeline of new customers that we believe will generate significant revenues in the medium term.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.